VBIV VBI Vaccines Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VBIV

Price (delayed)

$0.59

Market cap

$16.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.03

Enterprise value

$46.13M

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment ...

Highlights
The gross margin has soared by 95% YoY and by 25% QoQ
VBI Vaccines's gross profit has soared by 62% YoY and by 20% from the previous quarter
The equity has plunged by 88% YoY and by 62% from the previous quarter
The quick ratio has shrunk by 82% YoY and by 33% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.vbivaccines.com
Peers: CRIS VSTM ALIM MYGN

Key stats

What are the main financial stats of VBIV
Market
Shares outstanding
28.43M
Market cap
$16.78M
Enterprise value
$46.13M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.86
Price to sales (P/S)
1.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.31
Earnings
Revenue
$8.68M
EBIT
-$86.44M
EBITDA
-$84.45M
Free cash flow
-$61.75M
Per share
EPS
-$6.03
Free cash flow per share
-$3.97
Book value per share
$0.32
Revenue per share
$0.56
TBVPS
$3.17
Balance sheet
Total assets
$86.95M
Total liabilities
$79.42M
Debt
$53.04M
Equity
$7.53M
Working capital
-$39.51M
Liquidity
Debt to equity
7.05
Current ratio
0.48
Quick ratio
0.31
Net debt/EBITDA
-0.35
Margins
EBITDA margin
-972.6%
Gross margin
-44.1%
Net margin
-1,069.3%
Operating margin
-920.4%
Efficiency
Return on assets
-92.8%
Return on equity
-462.4%
Return on invested capital
-325.7%
Return on capital employed
-770.7%
Return on sales
-995.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VBIV stock price

How has the VBI Vaccines stock price performed over time
Intraday
1.72%
1 week
3.51%
1 month
-21.57%
1 year
-79.93%
YTD
0.43%
QTD
-2.09%

Financial performance

How have VBI Vaccines's revenue and profit performed over time
Revenue
$8.68M
Gross profit
-$3.83M
Operating income
-$79.91M
Net income
-$92.84M
Gross margin
-44.1%
Net margin
-1,069.3%
The gross margin has soared by 95% YoY and by 25% QoQ
The net margin has soared by 90% YoY and by 24% from the previous quarter
VBIV's operating margin has surged by 88% year-on-year and by 15% since the previous quarter
VBI Vaccines's gross profit has soared by 62% YoY and by 20% from the previous quarter

Growth

What is VBI Vaccines's growth rate over time

Valuation

What is VBI Vaccines stock price valuation
P/E
N/A
P/B
1.86
P/S
1.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.31
VBI Vaccines's EPS has soared by 54% YoY and by 49% from the previous quarter
The equity has plunged by 88% YoY and by 62% from the previous quarter
VBIV's P/B is 36% below its 5-year quarterly average of 2.9 and 2.1% below its last 4 quarters average of 1.9
The P/S is 100% below the 5-year quarterly average of 370.8 and 94% below the last 4 quarters average of 18.2
VBI Vaccines's revenue has increased by 7% from the previous quarter

Efficiency

How efficient is VBI Vaccines business performance
VBI Vaccines's ROS has soared by 90% YoY and by 25% from the previous quarter
VBI Vaccines's ROA has decreased by 42% YoY but it has increased by 4.5% from the previous quarter
VBIV's ROE is down by 39% from the previous quarter
The ROIC has contracted by 13% from the previous quarter and by 3.3% YoY

Dividends

What is VBIV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VBIV.

Financial health

How did VBI Vaccines financials performed over time
The total assets is 9% greater than the total liabilities
The quick ratio has shrunk by 82% YoY and by 33% QoQ
The current ratio has dropped by 77% year-on-year and by 26% since the previous quarter
The debt to equity has soared by 166% from the previous quarter
The equity has plunged by 88% YoY and by 62% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.